Technical Analysis for RENB - Renovaro Biosciences Inc.

Grade Last Price % Change Price Change
F 1.53 -10.00% -0.17
RENB closed down 10.0 percent on Friday, April 26, 2024, on 3.1 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 10
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Expansion Breakdown Bearish Swing Setup 0.00%
Reversal New Lows Setup Bearish Swing Setup 0.00%
Volume Surge Other 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%

   Recent Intraday Alerts

Alert Time
Down 10% about 20 hours ago
Outside Day about 20 hours ago
Fell Below Previous Day's Low about 20 hours ago
10 DMA Resistance about 21 hours ago
60 Minute Opening Range Breakdown about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Renovaro Biosciences Inc. Description

Enochian Biosciences Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-DB-01, a therapeutic cancer vaccine for the long term maintenance and prevention of relapse for the treatment of stage III and IV colon cancer patients; ENOB-DC-11 Innovative DC vaccine for multiple solid tumors; and ENOB-DC-21 for intratumoral injection. The company has strategic partnerships with The Scripps Institute and Fred Hutchinson Cancer Center. Enochian BioSciences was incorporated in 2017 and is based in Los Angeles, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Solid Tumors Infectious Diseases Vaccines HIV Cancer Vaccine

Is RENB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.25
52 Week Low 0.3928
Average Volume 336,824
200-Day Moving Average 2.93
50-Day Moving Average 2.55
20-Day Moving Average 2.40
10-Day Moving Average 2.09
Average True Range 0.31
RSI (14) 24.81
ADX 24.54
+DI 10.91
-DI 25.58
Chandelier Exit (Long, 3 ATRs) 2.11
Chandelier Exit (Short, 3 ATRs) 2.44
Upper Bollinger Bands 3.18
Lower Bollinger Band 1.62
Percent B (%b) -0.06
BandWidth 65.16
MACD Line -0.29
MACD Signal Line -0.20
MACD Histogram -0.0834
Fundamentals Value
Market Cap 102.85 Million
Num Shares 67.2 Million
EPS -0.71
Price-to-Earnings (P/E) Ratio -2.15
Price-to-Sales 0.00
Price-to-Book 5.19
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.43
Resistance 3 (R3) 2.52 2.31 2.28
Resistance 2 (R2) 2.31 2.08 2.27 2.23
Resistance 1 (R1) 1.92 1.94 1.82 1.83 2.18
Pivot Point 1.71 1.71 1.66 1.67 1.71
Support 1 (S1) 1.32 1.48 1.22 1.23 0.88
Support 2 (S2) 1.11 1.34 1.07 0.83
Support 3 (S3) 0.72 1.11 0.78
Support 4 (S4) 0.63